A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Trifluridine
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 23 Jan 2017 Results published in the Investigational New Drugs.
- 21 Dec 2015 Planned End Date changed from 1 Apr 2014 to 1 May 2016 as per ClinicalTrials.gov record.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.